101 results about "Bacteroides fragilis" patented technology

The invention provides isolated polypeptide and nucleic acid sequences derived from Bacteroides fragilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparation of a composition for treating inflammatory bowel diseases. The experiments show that bacteroides fragilis is safe and nontoxic and strong in pharmacologic action, and has good treating effect of treating inflammatory bowel diseases, thereby indicating that the bacteroides fragilis has good edible and medicinal prospects. According to the invention, a novel use of bacteroides fragilis is explored and a novel application field is developed. Bacteroides fragilis as a probiotic can be used for preparing foods or medical compositions for treating inflammatory bowel diseases so as to provide health-cared foods or treating medicines suitable for human body to take.

The invention relates to Bacteroides fragilis and applications thereof, particularly to Bacteroides fragilis ZY-312 having the preservation number of CGMCC No.10685, and applications of the Bacteroides fragilis ZY-312 in preparation of medicines, pharmaceutical compositions, foods, health products and food additives for prevention and / or treatment of antibiotic-associated diarrhea, wherein the Bacteroides fragilis ZY-312 is preserved in the China general microbiological culture collection center on April 2, 2015, has the preservation number of CGMCC No.10685, does not contain enterotoxin gene bft, has characteristics of significantly-improved cholate resistance and significantly-improved gastric acid resistance compared to the existing Bacteroides fragilis, and can effectively prevent and / or treat antibiotic-associated diarrhea.

The invention provides an application of bacteroides fragilis ZY-312 to prevention and / or treatment of inflammatory bowel diseases (IBDs), including an application of bacteroides fragilis ZY-312 to preparation of medicines, medicine compositions, food, health care products, food additives, and the like for preventing and / or treating IBDs. In vivo and in vitro related experiments confirm that bacteroides fragilis ZY-312 has excellent resistance to the IBD, including ulcerative colitis or the Crohn's disease, does not have toxic or side effect and can be permanently and effectively applied to preparation of the medicines, medicine compositions, food, health care products or food additives for preventing and / or treating IBDs. The medicines, medicine compositions, food, health care products or food additives can be used for preventing and treating IBDs and have important application values.

The invention discloses a biomarker capable of detecting diseases. The biomarker at least comprises one of the following microbes or the combination of the following microbes: Akkermansia muciniphila, Bacteroides fragilis, Clostridium bolteae, Clostridium hathewayi, Clostridium sp.HGF2, Clostridium symbiosum, Eubacterium limosum, Lactobacillus fermentum, Lactobacillus salivarius, Ruminococcus torques, Streptococcus anginosus, Streptococcus infantis, Bacteroides stercoris, Bacteroides uniformis, Bilophila wadsworthia and Clostridiales sp.SS3 / 4. The invention further discloses an application of the biomarker for determining inflammatory bowel diseases. The invention also discloses a method, a system and a kit for detecting the biomarker in a tested object. According to the invention, through the research on intestinal flora, and through the high-throughput genome sequencing, the biomarker with high relativity with the inflammatory bowel diseases is screened out, and then the biomarker is utilized for accurately and efficiently detecting and diagnosing the inflammatory bowel diseases, and further used for monitoring the treatment effect for the disease.

The subject matter of the present invention is a bacteria or mix of bacteria having an antagonistic activity with respect to stains of S. aureus, P. aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and / or Malassezia furfur as well as the use thereof in the treatment and / or prevention of infections or colonisations related to those pathogens. The invention pertains to care products containing one or more non-pathogenic antagonistic strains intended to prevent and / or treat infections or colonisations on skin, wounds, mucous membranes and appendages.

The invention relates to a preparation method of bacteroides fragilis capsular polysaccharide A. The preparation method comprises the following steps: preparing a bacterial suspension of bacteroides fragilis with the pH value of less than or equal to 5, heating and extracting, and collecting an extracting solution to obtain a crude sugar solution of capsular polysaccharide A. Compared with the prior art, the preparation method has the following beneficial effects that the inventor accidentally finds that the capsular polysaccharide A can be effectively promoted to fall off from the bacteroides fragilis thalli by heating and extracting the bacteroides fragilis bacterial suspension of which the pH value is less than or equal to 5, so that the capsular polysaccharide A is extracted. Compared with a traditional phenol / water method, the capsular polysaccharide A can be obtained under the condition that phenol is not used, and the toxicity is low. Moreover, by adopting the preparation method, the yield of the bacteroides fragilis capsular polysaccharide A is obviously improved.

The present invention relates to nucleic acid and amino acid sequences from Akkermansia muciniphila and from Bacteroides fragilis, coding for / representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose.

The invention relates to the technical field of application of bacteroides fragilis and particularly relates to bacteroides fragilis, and an application of a treatment or prevention composition, containing the bacteroides fragilis, for treating and / or preventing tumors. The invention also provides the bacteroides fragilis, as well as an application of preparing a medicine for treating and / or preventing tumors with the bacteroides fragilis, thus significantly inhibiting growth of tumors. The invention also provides applications of the bacteroides fragilis in preparation of medicine compositions, foods, healthcare products and food additives, which are used for treating and / or preventing tumors.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating acute radiation enteritis. Experiments show that bacteroides fragilis is safe, nontoxic and strong in pharmacologic action and has a good preventing and treating effect to acute radiation enteritis, thereby indicating that the bacteroides fragilis has good edible and officinal prospects. The invention explores novel use of bacteroides fragilis and develops a novel application field. Bacteroides fragilis serving as probiotic can be used for preparing foods or medical compositions for preventing and treating acute radiation enteritis.

The invention relates to a soil remediation agent. The soil remediation agent is prepared from the following components in parts by weight: 6 to 15 parts of photosynthetic bacteria, 10 to 12 parts of lactic acid bacteria, 2 to 7 parts of bacillus subtilis, 12 to 24 parts of actinomycetes, 0 to 2 parts of bacteroides fragilis, 3 to 5 parts of candida utilis, 0 to 3 parts of clostridium botlinum, 9 to 16 parts of nodule bacteria, 2 to 6 parts of thiobacillus, 4 to 14 parts of aspergillus niger, 13 to 26 parts of bacillus natto and 3 to 8 parts of thiobacillus; the strains are cultivated in respective culture mediums to form corresponding bacteria liquid. The soil remediation agent is also prepared from 7 to 11 parts of turfy soil and 1 to 5 parts of vermiculite. The soil remediation agent has insecticidal and fungicidal effects; according to the soil remediation agent, the fertilizer efficiency of soil can be improved, pests inside the soil and on the surface of the soil can be killed, the decomposition capacity of the soil is improved, organic matters are decomposed out, the remediation efficiency of the soil is high, the growing environment of crops is improved, and the yield is increased.

The invention relates to application of bacteroides fragilis or Akkermansia muciniphila to preparation of a drug for preventing or treating tumors. The drug promotes infiltration and / or accumulation of CD8 positive cytotoxic T lymphocytes in a tumor microenvironment. The invention further provides application of a drug composition, food, a health care product or a food additive for preventing or treating tumors, and the drug composition, the food, the health care product or the food additive includes the bacteroides fragilis or the akkermansia muciniphila and promotes infiltration and / or accumulation of the CD8 positive cytotoxic T lymphocytes in the tumor microenvironment.

The invention relates to the technical field of an application of bacteroides fragilis (BF) 839, in particular to an application of the bacteroides fragilis 839 to preparation of a medicine or food for treating or adjunctively treating immune-related diseases. The key effect of the bacteroides fragilis 839 in human intestinal tracts in treatment or adjuvant treatment of the immune-related diseasesis discovered for the first time, and the bacteroides fragilis 839 can be made into forms of pharmaceutical compositions, foods, health-care products or food additives by utilizing the key effect ofthe bacteroides fragilis 839 in the immune-related diseases. A pharmaceutical composition, a food, a health-care product or a food additive contains the bacteroides fragilis 839, can be used for treating the immune-related diseases, and has very important application value.

The invention provides a T cell immunity enhancing composition. The T cell immunity enhancing composition comprises bacteroides fragilis. The invention also discloses a tumor preventing and / or treating composition. The tumor preventing and / or treating composition comprises bacteroides fragilis.

The invention discloses an alpha-galactosidase and an expression and purification method thereof. The alpha-galactosidase is expressed by SEQ ID NO:1 in a sequence table, is obtained by encoding a recombinant genome DNA sequence SEQ ID NO:3 of bacteroides fragilis (Bacteroides fragilis) ATCC25285 and is a protein with effect of converting a red cell blood group of the human body from B-type into O-type and from AB-type into A-type. The alpha-galactosidase of the invention has the advantages of wide application, simple and convenient expression and purification method, low cost, important clinical and scientific research significance and wide market prospect.

The invention relates to applications of Bacteroides fragilis in treatment and / or prevention of obesity or diabetes mellitus, particularly to applications of Bacteroides fragilis in preparation of pharmaceutical compositions, foods, health products and food additives for treatment and / or prevention of obesity or diabetes mellitus, wherein the Bacteroides fragilis is ZY-312, is preserved in the China general microbiological culture collection center on April 2, 2015, and has the preservation number of CGMCC No.10685. According to the present invention, the Bacteroides fragilis provides good effects for treatment and / or prevention of obesity or diabetes mellitus, has characteristics of no drug resistance generation, safety, no toxicity, no enterotoxin gene bft and broad application prospects, and further has beneficial characteristics of cholate resistance, gastric acid resistance and the like compared with the existing strains.

The invention relates to application of a bacteroides fragilis extract in preparation of a medicine or food for preventing and treating irritable bowel syndrome. The bacteroides fragilis extract contains bacteroides fragilis capsular polysaccharide A. The bacteroides fragilis capsular polysaccharide A with the molecular weight of 5-70 KD is prepared accidentally, it is found accidentally that the capsular polysaccharide A with the molecular weight of 5-70 KD has a better function of preventing and treating the irritable bowel syndrome, and the effect of the capsular polysaccharide A is far better than that of the capsular polysaccharide A with the molecular weight of 110 KD extracted from bacteroides fragilis NCTC 9343.

The invention discloses bacteroides fragilis capable of regulating and controlling relative abundance of akkermansia in intestinal tracts, and belongs to the technical field of microorganisms. The bacteroides fragilis CCFM1123 is screened out, and the bacteroides fragilis CCFM1123 has the effect of relieving inflammation. Specifically, the relative abundance of lactobacillus and akkermansia in theintestinal tract of an inflammatory mouse is remarkably improved; the content of proinflammatory factors TNF-alpha and IL-6 in the serum of the inflammatory mouse is remarkably reduced; intestinal inflammatory cell infiltration and mucosal bleeding caused by inflammatory response of the inflammatory mouse are remarkably reduced; and production of short-chain fatty acids in the intestinal tract ofthe inflammatory mice is obviously promoted. Therefore, the bacteroides fragilis CCFM1123 has a huge application prospect in preparation of products (such as foods or medicines) for preventing and / ortreating inflammation.

The invention belongs to the biotechnical field of foods, and concretely discloses a preparation method of fermented wheat germs. The preparation method comprises the following steps: 1, selecting high quality wheat, germinating the wheat, and keeping the water content unchanged in a range of 45-55% after malts just germinate; 2, inoculating aroma-producing yeast and BF839 Bacteroides fragilis, carrying out aerobic fermentation, inoculating bifidobacteria after fermentation is carried out for a certain time, filing a closed container with the obtained wheat, and carrying out anaerobic fermentation; 3, carrying out low temperature drying after fermentation ends; 4, degerming the dried wheat; and 5, adding sweet potato powder and high fructose syrup to degermed wheat germs, and puffing or baking to obtain the fermented wheat germs. Germinated wheat is fermented, degermed and post-processed to obtain the fermented wheat germs. The fermented wheat germs obtained in the invention contain abundant nutrients, contain aroma substances specially possessed by wheat, also have the baked sweet potato flavor, and has abundant nutrition values and unique flavor.

The invention relates to application of bacteroides fragilis to preparation of an enhancing agent for enhancing an intestinal mucosal barrier function. According to a great quantity of experiments, the bacteroides fragilis has functions of repairing intestinal epithelium mucus barrier and reducing intestinal mucosal permeability and is capable of effectively enhancing the intestinal mucosal barrier function to protect human health.

The invention brings forward biomarkers for end-stage renal disease and an application thereof. The biomarkers for end-stage renal disease are Akkermansia muciniphila, Alistipes finegoldii, Alistipesshahii, Bacteroides fibrobacter, Bacteroides fragilis, Bifidobacterium dentium, Clostridium difficile, Clostridium saccharolyticum, Desulfovibrio Vulgaris, Eggerthella lenta, Enterococcus faecalis, Enterococcus faecium, Flavonifractor plautii, Fusobacterium nucleatum, butyric acid-producing enterobacteriaceae, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus infantarius, Streptococcus thermophilus, butyrate-producing bacteria, Eubacterium rectal and Faecalibacterium prausnitzi. Whether a subject suffers from or is susceptible to end-stage renal disease can be effectively determined by determining these microbial markers in the intestinal flora of the subject.

The invention discloses an alpha-galactosidase and an expression and purification method thereof. The alpha-galactosidase is expressed by SEQ ID NO:1 in a sequence table, is obtained by encoding a recombinant genome DNA sequence SEQ ID NO:3 of bacteroides fragilis (Bacteroides fragilis) ATCC25285 and is a protein with effect of converting a red cell blood group of the human body from B-type into O-type and from AB-type into A-type. The alpha-galactosidase of the invention has the advantages of wide application, simple and convenient expression and purification method, low cost, important clinical and scientific research significance and wide market prospect.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating hypercholesteremia. Experiments show that bacteroides fragilis is safe, nontoxic and strong in pharmacologic action and has good preventing and treating effect to hypercholesteremia, thereby indicating that the bacteroides fragilis has good edible and officinal prospects. The invention explores novel use of bacteroides fragilis and develops a novel application field. Bacteroides fragilis as probiotic can be used for preparing foods or medical compositions for preventing and treating hypercholesteremia so as to provide a clinically health-care and preventing and treating food suitable for human to take.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to an application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals. The invention explores a novel use of bacteroides fragilis and opens up a novel application field. Experiments show that bacteroides fragilis as a kind of probiotics can be used for preparing animal feed additives to prevent intestinal diseases of animals so as to promote healthy growth of animals.

Provided is a marker for determining a mental disease, which can be used for an objective diagnosis of a mental disease. A marker for determining a metal disease, which comprises at least one enterobacterium selected from those belonging to Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens and Enterobacteriaceae.

The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and / or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterialactivity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparation of a composition for treating bacterial vaginitis. The experiments show that bacteroides fragilis is safe and nontoxic and strong in pharmacologic action, and has good treating effect to treat bacterial vaginitis, thereby indicating that the bacteroides fragilis has good edible and medicinal prospects. According to the invention, a novel use of bacteroides fragilis is explored and a novel application field is developed. Bacteroides fragilis as a probiotic can be used for preparing foods or medical compositions for treating bacterial vaginitis.

The invention relates to an application of bacteroides fragilis in the preparation of a composition for treating constipation. The bacteroides fragilis is used for preparing a carrier, and also can be used for preparing the composition of a food or a drug containing the microorganism. An experiment proves that the bacteroides fragilis has a good treatment effect on constipation; the bacteroides fragilis not only can supply physiological bacteria for an intestinal tract, corrects flora disturbance of the intestinal tract during constipation, and promotes digestive absorption of the food; various organic acids are also formed in the process of metabolization of the intestinal tract; and an acidic environment is built in the intestinal tract. Therefore, the pH value of the intestinal tract can be reduced; normal peristalsis of the intestinal tract is facilitated; meanwhile, spoilage organisms are inhibited; the adverse effect of harmful metabolites on the intestinal tract generated by the spoilage organisms of the intestinal track is reduced; enteroplegia is prevented; and the prepared drug is good in effect of treating the constipation, free of side effect, safe and reliable.

The invention provides a liquid-solid combined fermentation process for Bacteroides fragilis. The process comprises a first step of preparing a liquid nutrient solution from, by weight, 0.5 to 2.5% of peptone, 0.2 to 0.5% of glucose, 0.001 to 0.5% of cysteine, 0.2 to 0.5% of NaCl, 0.1 to 0.3% of NaHPO4, 0.02 to 0.1% of sodium thioglycolate, 30 to 60% of liquid ox liver extract, 30 to 60% of liquid beef extract and 0.1 to 0.8% of yeast extract. The process provided by the invention employs liquid-solid combined fermentation, and a great amount of Bacteroides fragilis can be obtained in a short period of time by using the process; and the process has the advantages of easiness, small investment, easy controllability in operation, small possibility of infection with competitors due to implementation of all the operations under vacuum and aseptic conditions and high concentration of bacterial strains.